Molecule guides
Fertility and Hormone Research Peptides: HPG-Axis Overview, Compound Classes and How to Choose
A level-by-level map of the HPG axis covering kisspeptin-10, gonadorelin, triptorelin, HCG, HMG and enclomiphene, plus the sampling rules that make LH data interpretable.
Among the research areas in this catalogue, reproductive endocrinology stands out because the biology behind it is genuinely mature. Few control circuits have been charted as thoroughly as the hypothalamic-pituitary-gonadal (HPG) axis: kisspeptin-expressing neurons set the rhythm of the GnRH pulse generator, each GnRH pulse prompts the pituitary to release LH and FSH, those gonadotropins in turn govern steroid output and gamete formation in the gonads, and circulating sex steroids feed back to close the circuit. Each compound discussed below intervenes at one identifiable step. The catch is that several of them push the system down rather than up — the opposite of what a label such as "fertility peptides" suggests. What follows is a map of the axis, a side-by-side look at the reference compounds, and a practical framework for choosing between them.
Mapping the axis: the site of action for each compound
The rhythm originates in the arcuate nucleus, where a single neuronal population expresses kisspeptin, neurokinin B and dynorphin together. These KNDy cells fire in synchrony, and that coordinated firing generates the GnRH pulses on which every downstream step relies. Kisspeptin binds KISS1R and triggers GnRH secretion. GnRH then travels via the hypophyseal portal vessels to the anterior pituitary, where pulsatile delivery prompts gonadotrophs to secrete LH and FSH. In the gonad, LH targets Leydig and theca cells to support steroid synthesis, while FSH targets Sertoli and granulosa cells to support gamete development. Sex steroids then exert negative feedback on both the hypothalamus and the pituitary.
Each compound slots neatly into this scheme. Kisspeptin analogues work at the apex. GnRH and its agonists sit one tier lower, and whether they stimulate or suppress depends wholly on the dosing pattern used in the experiment. Gonadotropins and related analogues act directly on the gonad. Selective estrogen receptor modulators do not stimulate any tier themselves; they lift the steroid feedback brake instead.
Endpoints and measurement in HPG-axis studies
Dense sampling is the methodological requirement that defines this field. Because LH leaves the pituitary in discrete bursts separated by intervals of tens of minutes, one isolated blood draw lands at a random phase of the rhythm and may catch a peak or a trough irrespective of any intervention. Established designs therefore draw samples every 10–15 minutes across a four- to eight-hour window and apply a pulse-detection algorithm to the series. Further endpoints include FSH, testosterone, estradiol and progesterone; anti-Müllerian hormone as an index of ovarian reserve; sperm count, motility and morphology; histological follicle counts; and, in rodent work, vaginal cytology to determine cycle stage. For mechanistic studies, multi-unit electrophysiological recording from the arcuate nucleus reads out pulse-generator activity directly and remains the reference method.
Compound classes used in this research
Kisspeptin analogues
Kisspeptin-10 corresponds to the final ten C-terminal residues of kisspeptin-54, has a molecular weight of 1302.47 Da, and signals through KISS1R, the receptor originally catalogued as GPR54. The way its role was uncovered is a textbook case in reproductive biology: humans carrying inactivating KISS1R mutations present with hypogonadotropic hypogonadism, which identified the receptor as an obligatory gate for GnRH secretion. Academic teams — Imperial College London prominent among them — have run human physiology studies measuring LH responses to kisspeptin in healthy volunteers and in people with reproductive disorders. A brief measured half-life limits its usefulness, and that limitation is exactly why longer-acting analogues were developed.
GnRH and GnRH agonists
Gonadorelin is simply native GnRH — a decapeptide of 1182.29 Da. Diagnostically it is used to probe how well pituitary gonadotrophs respond, and when delivered in pulses it drives the axis forward. Triptorelin, at 1311.45 Da, is a superagonist in which position 6 carries a D-tryptophan; this change slows enzymatic breakdown and increases receptor affinity. Its pharmacology illustrates the least intuitive principle in the whole field: sustained, non-pulsatile agonist exposure downregulates the receptor and desensitises gonadotrophs, so that after a brief initial surge, LH and FSH secretion falls. Clinical use in hormone-dependent disease rests on this effect — and it means one molecular class can yield opposite endocrine results depending solely on the exposure pattern.
Gonadotropins
HCG is a glycoprotein hormone whose alpha subunit is identical to that of LH, FSH and TSH; it signals through the LH/CG receptor. An extended C-terminal peptide on its beta subunit is what gives it a longer half-life than LH. HMG (menotropins) is extracted from urine and carries both FSH and LH activity. Each is a prescription-only medicine and appears in this catalogue purely as a reference entry. Because both are glycoproteins rather than synthetic peptides, their strength is stated in international units determined by bioassay, not in milligrams of mass — a difference any protocol that includes them has to account for.
Feedback modulators
Enclomiphene, the trans-isomer of clomiphene, is a selective estrogen receptor modulator with a molecular weight of 405.96 Da in citrate form. It raises endogenous LH and FSH by blocking estrogen's negative feedback at hypothalamic and pituitary level — an indirect route that only works if the axis above it is functional. A development programme aimed at a particular male indication ended without approval, so it remains an unapproved investigational substance.
Side-by-side: reference compounds along the reproductive axis
Pay closest attention to the direction column. Two compounds acting on the GnRH receptor carry opposite entries, and what separates them is the exposure pattern, not the chemistry.
Evidence base, grouped by type of study
Mechanistic animal studies
Multiple independent groups have backed the KNDy pulse-generator model using electrophysiology, optogenetic stimulation and receptor knockouts, making it one of the firmest mechanistic accounts in neuroendocrinology. Genetic data from both mice and humans show that puberty cannot begin without kisspeptin signalling. Loss of GnRH receptor responsiveness under sustained exposure is a long-standing pharmacological finding that has been reproduced many times.
Human physiology studies
Academic groups operating under formal research protocols have given kisspeptin to human participants and recorded the LH response in healthy subjects, in hypothalamic amenorrhoea and in further reproductive conditions. Gonadorelin has an established diagnostic track record. Triptorelin, HCG and HMG are authorised medicines, each supported by extensive clinical trial data for its approved uses.
Where the evidence is weaker
Because enclomiphene's development did not end in approval, it should be presented as an investigational substance and not as an established agent. No clinical evidence applies to research-grade material of any compound on this page — trial results relate to pharmaceutical products manufactured and characterised to separate standards.
Selecting fertility and hormone peptides for a study
- At which tier of the axis is the question posed? Pulse-generator questions point to kisspeptin, questions about pituitary responsiveness point to gonadorelin, and gonadal questions point to a gonadotropin. Probing the wrong tier yields data about a different component of the system.
- Will exposure be pulsatile or sustained? For the GnRH-type compounds this decides everything and is the most frequent source of misunderstanding here: pulses stimulate, constant exposure suppresses.
- Is the axis functionally intact? Enclomiphene acts by lifting feedback and depends on working hypothalamic and pituitary tissue. A hypophysectomised or knockout model gives it no pathway to act on.
- Is the sampling schedule sufficient? Hormones released in pulses need frequent draws plus pulse-detection analysis; a single LH value says nothing reliable about axis function.
Products relevant to this area are collected under peptides for fertility and hormones, and the mechanism-based grouping is listed as hormonal and fertility peptides. Two head-to-head pages answer the most frequent questions: kisspeptin-10 against gonadorelin by level of action, and HCG against HMG by gonadotropin content.
Supply formats and handling
Synthetic peptides in this group are normally supplied as lyophilised vials, which lets the researcher fix a precise molar concentration. Glycoprotein hormones, by contrast, are specified in bioassay-derived international units rather than by weight, since variable glycosylation means identical masses of different batches do not deliver identical biological activity — a real categorical difference from synthetic peptides that protocols need to reflect. Kisspeptin is also available as sublingual troches and nasal formats at a fixed pre-diluted strength; these suit route-comparison studies but not designs where concentration is itself the variable.
On handling: kisspeptin-10 and GnRH are compact peptides that keep well as dry powder yet clear quickly from circulation, which is why physiology studies often favour infusion over single bolus delivery. Oxytocin ranks among the least solution-stable of the common research peptides, and the certificate should confirm that its disulfide bridge is correctly formed. Glycoprotein preparations tolerate temperature stress less well than synthetic peptides and lose activity through repeated freeze–thaw cycles. Store all lyophilised material sealed at -20 °C away from light, and divide it into aliquots when reconstituting.
Frequent study-design mistakes
Mistake one: measuring gonadotropins at a single time point, for the reasons explained above. It is the error seen most often in this literature, and it does not merely weaken the main endpoint — it renders it invalid.
Mistake two: failing to account for cycle stage in female animals. Circulating hormones and hypothalamic responsiveness shift considerably through the estrous cycle, so unstaged cohorts add variance that often exceeds the size of the treatment effect. Staging by vaginal cytology is inexpensive and standard practice.
Mistake three: mixing up units. Synthetic peptides are quantified by weight and glycoprotein hormones by bioassay units, and no conversion factor links the two. A protocol that combines both systems without specifying which applies to which compound cannot be reproduced.
Mistake four: treating a lone hormone value as evidence about fertility. Serum LH or testosterone is only an intermediate marker; the endpoints that actually support a fertility claim are gamete parameters, follicle counts or pregnancy outcomes in a suitable model.
Mistake five: assuming that an endocrine effect seen in one sex applies to the other. Both sexes share the same axis layout but regulate it differently. In males, negative feedback is fairly constant; in females it switches periodically into a positive-feedback state that drives the preovulatory LH surge, and this is mediated by a separate kisspeptin population in the anteroventral periventricular nucleus. Data from males do not characterise a compound in females (and vice versa), and the surge mechanism has no counterpart in males at all.
Mistake six: overlooking how slowly the gonads respond. Steroid synthesis reacts to gonadotropin input within hours, whereas gamete production runs on a far longer clock: in humans, spermatogenesis needs roughly seventy-four days to progress from spermatogonial division to mature sperm, and folliculogenesis from primordial recruitment through to ovulation takes several months. A study that assesses sperm four weeks after an intervention begins has not waited for a complete spermatogenic wave, so its results mostly describe gametes that were already well on their way at baseline.
Purity, identity confirmation and regulatory position
Because the synthetic peptides here are short, they should reach at least 98% purity by HPLC, with identity verified by mass spectrometry. Gonadorelin carries a C-terminal amide and an N-terminal pyroglutamate, and both modifications should be verified by mass rather than taken for granted. Triptorelin is defined by its D-tryptophan at position 6, yet that substitution leaves the nominal mass identical to the L-form — so stereochemistry has to be confirmed by chromatography, not mass spectrometry, one of the few cases in this catalogue where the distinction has real practical weight. Glycoprotein preparations are characterised through bioassay potency and glycoform profiling rather than HPLC purity.
Triptorelin, HCG and HMG are prescription medicines shown only for reference; the research-grade material supplied is not those medicinal products. Enclomiphene is an investigational compound whose development programme did not end in approval. Neither kisspeptin-10 nor gonadorelin is approved as a therapeutic agent in the United States, although gonadorelin has a history of diagnostic use. All material referred to on this page is research-grade, intended for laboratory research only and not for human consumption.
Questions
What does the term KNDy pulse generator refer to?
It describes a group of arcuate-nucleus neurons that express kisspeptin, neurokinin B and dynorphin together. When these cells fire in synchrony they generate the GnRH pulses that the whole reproductive axis runs on. Electrophysiology, optogenetic stimulation and receptor knockouts from several independent groups support the model, which counts among the most robust mechanisms described in neuroendocrinology.
How can a GnRH agonist end up suppressing the reproductive axis?
The GnRH receptor only keeps signalling when it is stimulated in pulses. Under sustained agonist exposure the receptor is downregulated and gonadotrophs become desensitised, so once the early flare passes, LH and FSH secretion drops. Delivering the same compound in pulses has the reverse effect — the molecule is unchanged, and the exposure pattern alone sets the direction.
What makes kisspeptin the master switch of reproduction?
Humans with inactivating mutations in its receptor, KISS1R, develop hypogonadotropic hypogonadism, and mice lacking the equivalent gene never go through puberty. This genetic evidence shows the receptor is required for GnRH secretion, not simply a modulator of it — a stronger position than most signalling molecules in reproductive biology can claim.
Why are HCG and HMG dosed in international units instead of milligrams?
Both are glycoproteins with variable glycosylation, and the mix of glycoforms influences biological activity and half-life. Two preparations of equal weight can therefore differ in activity, so potency is set by bioassay and reported in international units. Synthetic peptides have a fixed structure and are specified by weight, and there is no conversion between the two systems.
In what way does enclomiphene work differently from the peptides on this page?
Rather than acting on the axis itself, it targets the feedback loop. As a selective estrogen receptor modulator it prevents estrogen from exerting negative feedback on the hypothalamus and pituitary, and endogenous LH and FSH rise as a result. Because this route is indirect, it depends on an intact axis — a hypophysectomised or receptor-knockout model offers it nothing to work through.
Why must cycle stage be recorded in female study animals?
Hormone concentrations and hypothalamic responsiveness change markedly over the estrous cycle. Animals sampled at different stages will differ hormonally for reasons unrelated to treatment, and this background variation often exceeds the effect under investigation. Routine vaginal cytology staging is cheap and removes the problem.
What method confirms the identity of triptorelin?
Chromatography rather than mass measurement. Triptorelin is defined by a D-tryptophan at position 6, and a D-amino acid has exactly the same nominal mass as the L-form, so mass spectrometry cannot tell them apart. A chiral or reverse-phase chromatographic separation using a stated method is what demonstrates that the material is the superagonist and not native GnRH.